Index

Abortion

fetus, legal status of, 33-34 electronic health records, 395-397 information to be included, 396 use for secondary purposes, 397 Acupuncture – see Complementary medicine who is to have access to, 396-397 AIDS - see Public health end-of-life guidelines, 397-398 Medicare versus private health insurance, 394-Alternative medicine – see Complementary mini-medical school, 398 medicine Capacity to decide Anorexia nervosa refusal of treatment - see Medical treatment competence of patients with, 316-324, 445 research on, 317-324 discussion, 318-321 Cervical manipulation method, 317 definition of, 174 results, 317-318, 322-324 information exchange regarding, 178-186 confidentiality of patients with, 316-324 assessing patient's knowledge and perceptions, 181-182 style of communication, 178-180 Automatism, 61-68 timing of information, 181 common law verbal communication, 180-181 alteration to approach, possible, 67 how deals with, 64 reinforced by written information, 182-183 video or computer, by, 184 conditions in which occurs, 63 definition of, legal, 62-63 written communication, 183-184 learnability, 184 diabetes and, 62, 67 epilepsy and, 61, 62, 63, 66 legibility, 184 readability, 183-184 non-common law approach, 65-66 reinforcing verbal communication, 182recent changes, 66 183 "sane" or "insane", 61-62, 64-65, 67 informed consent clinical practice and, 176-178 Autopsies - see Death, investigation current physiotherapy practice, 184-185 legal obligations, 175-176 pre-manipulative screening guidelines, 176-178 Bioterrorism - see Public Health studies of, 175 Birth, wrongful - see Wrongful life claims Child see also Anorexia nervosa; Fetus **Blood tests** competence of, 310-314, 443 consent, without, 110-113 consent to treatment, 310-313 court order to take blood, 111-112 refusal of treatment, 313-314 necessity or emergency, 112-113 test of. 311-312 person in motor/boating accident, 110 confidentiality rights, 314-315 police assess person as drug-impaired, 110involuntary treatment, 84-96 111 best interests, 92 child life specialist, 95 Breach of confidence - see Medical records guidelines for ethical practice, 95

Canada

legal implications, 91-93	criteria for assessment of, 7
multidisciplinary context, 95	evidence-based medicine
nursing practice guidelines, 93-95	definition, 5
parental responsibility, 92	levels of evidence, 5
research study of leukaemia patients, 85-87	forensic relevance of, 6-8
demographics, 86	future of, 8-9
discussion, 91	international developments, 6
findings, 87-91	
child's distress, 87, 88	Cloning
ethical issues, 91	see also Stem cell research
hardest aspect of treatment, 87	definition, inadequacy of, 523-524
health professionals, role of, 89	Dolly the sheep, 516
holding child down, 87	prohibition on, 490, 502, 522, 523, 524
hospital setting, difficulties of, 88	Prohibition of Human Cloning Bill 2002, 524
mothers'/fathers' role, 89	525
parent/child relationship, impact on, 89	developments leading up to, 522-525
parents' distress, 87-88	embryo types distinguished, 525-526
parents' perception of need to hold	limitations of, 528-529
child	prohibited practices, 526
down, 89	review of, 529, 530
preventative strategies, 89-91	reproductive, 515, 516
stress, dealing with, 88-89	Dolly the sheep, 516
methodology, 85-86	emotional outrage, 524
target population, 86	ethical considerations, 520-521
leukaemia treatment of, 84-95	European ban on, 516
treatment when parents refuse consent, 442-459	infertility, to overcome, 521
child representative, 457	prohibition on, 490, 502, 521, 523, 524, 525-
child welfare legislation, 447-449	526
current framework, 452-454	success rates of, 516
ex-nuptial children, 450-452, 453-454, 457	somatic cell nuclear transfer, 516
jurisdiction to adjudicate cases, 444-447, 459	ban of, 529
Children's Courts, State, 444, 447-449,	therapeutic, 515, 516
452, 459	arguments against, 521
Family Court, 444, 449-452, 453-457, 459	ethical considerations, 521
case management procedures, 454-456	regulation of, 523, 524
preference, 454-457	therapeutic benefits of, 521, 523
schematic of various jurisdictions, 459	
Supreme Courts, State, 444-447, 449, 450,	Communications, confidential – see Confidential
452, 459	communications legislation
Office of the Public Advocate, 452, 456, 459	
parens patriae power, 444-447, 449, 450, 452	Compensation
reform, implications for, 457-458	psychiatric injury, for – see Psychiatric injury
special medical procedures, 451, 454, 456-	
457	Competence
guidelines for, 456	see also Child; Consent
	anorexia nervosa, consideration of, 316-317
Chinese medicine – see Complementary	research on, 317-324
medicine	discussion, 318-321
	method, 317
Clinical practice guidelines, 5-9	results, 317-318, 322-324

consent, for, 92-93	obligations of, 269-270
Gillick-competency, 92-93, 311-312, 315	regulation of, 290-291
minors and, 310-313	training of, 274, 287, 301, 306
test of, 311-312	private health insurance position, 274
minors	regulation of, 257-258
consent to treatment, 310-313	Chinese medicine, 291
refusal of treatment, 313-314	claims made about products, 289
	Commonwealth Government, by, 273-274
Complementary medicine	medicines, 289
acupuncture, 257, 300	practitioners, 290-291
endorsing practice of, 259	clinical competence of, 291-293
AMA position on, 273, 278, 283	Victorian Government, by, 274
categories of, 307	usage of, 257
Chinese medicine, 258	increasing, 272, 287
endorsing practice of, 258	warning of risks, 270, 305-306
evidence-based, 293-295	2 , ,
regulating practitioners, 285-295	Conception, wrongful - see Wrongful life claims
clinical competence of, 292-293	
chiropractors, 300, 306	Confidential communications legislation, 49-60
obligations of, 306	introduction of, 51-53
defining, 286, 296, 298-299, 303-304	New South Wales, 56-60
doctor's duty to provide information about, 271-	application of privilege in civil and criminal
284, 297-302	proceedings, 58
autonomy, emphasis on, 301	judicial discretion, 57-58
case law, 297-298	procedural scope of legislation, 57
chiropractors' obligations, 306	professional confidential relationship
establishing reasonably available alternative	privilege, 56-57
treatment options, 279-282	protected counselling communication
materiality test, 276-279, 282-283, 297	privilege, nature of, 59-60
New Zealand Guidelines, 298-299, 301-302	sexual assault communications privilege, 56-
NHMRC Guidelines, 275, 277, 279, 297	57
patient questions, answering, 278, 301	public interests, balancing, 49-51, 52
physiotherapy obligations, 303	fairness of trial, 49, 50, 52
reasonableness, test of, 276-277	preserving therapeutic confidentiality, 49-50
training, lack of, 301	52
types of information, 275	purpose of, 51-53
unlimited practitioners, as, 302	South Australia, 55-56
education on, 274, 287, 301, 306	judicial discretion, 56
evidence-based, 293-295, 298-299	nature of protected communications, 56
herbal medicine, 300	public interest immunity, scope of, 55
homeopathy, 300	Victoria, 53-55
incorporation into general practices, 272-273	limits on judicial discretion, 54
physiotherapy, 303	nature of protected communications, 54-55
popularity of, reasons for, 287-289	procedural scope of legislation, 53-54
practitioner	procedural scope of legislation, 55 54
advising on orthodox medicine options, 302	Confidentiality
awareness of orthodox medicine required, 270	see also Confidential communications
clinical competence, regulation of, 291-293	legislation; Medical records; Privacy
duty of care, 270, 305	anorexia nervosa, patients with, 316-317
limited role of, 303-304	research on. 317-324

discussion, 318-321	length of time required, 391
method, 317	earning capacity, loss of, 390
results, 317-318, 322-324	general, 390
minor patients' rights, 314-315	non-pecuniary loss, for, 389, 390
patients' possessions, regarding, 113-114	structured settlement, 391
patients possessions, regarding, 115 111	taxation of, 391
Conjoined twins	Databases – see Data registers
necessity, defence of, 12-13, 14, 15	
	Data registers, 69-83
Consent	see also GeneTrustee; Privacy
see also Blood tests; Cervical	coded data, 74-75
manipulation; Child; Medical records; Research	consent for storage and use of information, 507-508
competence for, 92-93	de-identified data, 74, 81
child, by, 310-313	ethics committee involvement, 70, 71, 76, 78, 81
Gillick-competency, 92-93, 311-312, 315	"future-proofing" health data, 79-80
informed	guidelines, international, 507
clinical practice and, 176-178	Guthrie cards, use of, 507, 510
current physiotherapy practice, 184-185	human genetic, 506
legal obligations, 175-176	identifiable data, 70, 71, 75-77, 81
surgery, for, 409	legislation constraining, 83
	law, whether can help, 78-79
Copyright	legal regulation of, 72-74, 82
see also Gene technology	common law, 73
gene technology and, 97-108	complexity and fragmentation, 74
	legislation, 73
Coronary angiography	State, 73
informing patients of risks of, 168-173	State and federal, 73-74
study of, 169-173	name-identifying data, 75-77
discussion, 171-173	legislation constraining, 83
method, 170-171	patient consent to information, 70, 71, 72, 78, 81
overview, 169-170	privacy issues, 70-80, 507
results, 171	National Privacy Principles, 72, 73, 74, 76,
statistical analysis, 171	77, 79
	National Statement, 78, 79
Coroners	purpose of, 507
see also Death, investigation	disclosure of, 72, 507
findings of, requirements for, 399	re-identifiable data, 70, 71, 74-75, 81 research tool, as, 507
functions of, 399 recommendations of, effect of, 399-400	
	study of voluntary health data registers, 69-83 background and methodology, 70
Counselling	results, 70, 81
confidential communications – see Confidential	universal patient identifier, 79
communications legislation	voluntary, 70-71
	Death
Damages , 389-391	certification in United Kingdom, 155-157

cap on, calls for, 389-390

care of plaintiff, for, 390-391

investigation

Australia, in, 156-157

United Kingdom, in, 155-157 Embryo – see Stem cell research natural, 260-264 feeding and hydration, by stopping, 260-264 Emergency departments - see Nurses United Kingdom guidelines, 263 End-of-life guidelines, 397-398 Dementia, 260 see also Euthanasia Disability discrimination – see Discrimination **Epilepsy** causes of, 265 **Disclosure** trauma and, 265-266 medical records, of – see Medical records types of, 265 Discrimination Ethics, research of - see Research see also Genetic discrimination disability, 481, 483 Euthanasia, 221-238 meaning of, 477 see also Medications, opioid medical records, using, 461 doctors, role of, 221-231 racial, 481-482 doctor-centred arguments against, 226-227 duty to kill, 227-231 Disease control - see Public health best interests of patient, 230 better off dead, 229-230 Drugs counter-arguments, 230-231 see also Medications, opioid; Public health moral and legal obstacles to, 227-228 drug-dependent patients, treatment of, 109-117 right to die, 228-229 blood test without consent, 110-113 moral standing of, 224-226 court order to take blood, 111-112 duty to relieve suffering, 226 participation as basis for, 225 necessity or emergency, 112-113 person in motor/boating accident, 110 relevance of doctors' attitudes, 227 police assess person as drug-impaired, end-of-life guidelines in Canada, 397-398 110minors, of, 234 Netherlands, in, 221-222, 223-224, 232-238 111 defence of necessity, 223-224, 233 patient wants to use illicit drugs in hospital, ethical review, 234-235 116-117 suspicious objects in patient's possession, legislation and its background, 232-233 113-116 legislative control, 233-234 conceal item, 114, 115 medical self-regulation, 235-236 confidentiality requirement, 113-114 objections to legalising, 236-237 disposal of, 115 reasons for legalising, 223 looking after, 115 Northern Territory, in, 222 risk, where serious, 114 objections to legalising, 236-237 opioid medications used for, 145-146 fetus harmed by illicit, 32 **Duress** Evidence-based medicine, 5 defence of, 10

Volume 10 571

Feeding and hydration

artificial as medical treatment, 262 death by discontinuing, 260-264 reasonable provision of, 262-263

Duty of care – *see* Complementary medicine;

Electronic health records - see Medical records

Hospital; Wrongful life claims

Fetus	genetic tests, 472
abortion, 33-34	certainty, providing, 478
child protection law, effect of, 34-35	diagnostic tests, 473, 476, 485
criminal law, effect of, 29-34	fear of, 476-477
abortion, 33-34	Huntington's disease, 473, 478, 480
drugs, use of illicit, 32	impact of, 472-473
homicide and assault	insurance contingent on, 479, 480
"born alive" rule, 29-30	limitations of, 473, 474
common law, 29-31, 38	misinformed responses to, 474, 476-477
legislative intervention, 31-32, 38	predictive, 472, 473, 474, 476, 478, 484, 485
legal status of, 28-40	pre-symptomatic tests, 474, 476, 485
maternal-fetal relationship, 28, 30-31, 33, 36, 37-	prohibition on use of, 485-486
40	refusal to undergo, 483
medical intervention cases, 35-36	results, interpretation of, 473-477
negligence law, effect of, 36-37	diagnostic, pre-symptomatic or predictive
succession law, effect of, 28-29, 38	473-474
	errors in, 474-475
	health professionals, by, 474-475
Gene technology	impact of, wider, 476-477
see also Genetic discrimination; Stem cell	implications for individuals, 476
research	insurance companies, by, 475-476
background to, 471-472	health insurance, in, 478
copyright and, 97-108	indirect, 477
artistic craftsmanship, genetically modified	justified, when, 479
organism as work of, 105-107	life insurance, in, 470-487
artistic works, protection as, 104, 105-107	asymptomatic ill, against, 476, 482, 483, 486
artistic craftsmanship, work of, 105-107	complaints procedure, 483
sculpture, 105-107	cover contingent on test results, 479
judicial consideration, 99	disclosure, duty of, 478, 480-481, 482-483
literary work, protection as	discriminate, whether permitted to, 479-480
Australia, in, 102-103	discriminatory basis of insurance, 477-479
United Kingdom, in, 102	future, options for, 483-487
United States, in, 100	current system with alterations, 484-485
organism	genetic insurance product, 486
definition of, 104	genetics underwriters, 484
requirements for copyright, 104-105	moratorium, 485
sculpture, genetically modified organism as,	prohibit use of test results, 485-486 safety net approach, 485
105-107 United Kingdom, 101-102	genetic tests as prerequisite to insure, 480
United Kingdom, 101-102 United States, 99-101	incorrect risk assessment, 475
what can be protected, 98-99	legislation
genetic engineering, summary of, 98	critique of, 482-483
genetic engineering, summary or, 38	Genetic Privacy and Non-Discrimination
Genetic databases – see Data registers	Bill, 482, 483
Genetic databases – see Data registers	need for specific, 470
Genetic discrimination	options, future, 483-487
direct, 477	relevant, current, 480-482
effect of, 43	policy guidelines, 481, 483
environment, effect of, 471-472	risk assessment, 478
genetic techniques and technology, 471-472	meaning of, 477, 482
011	ω - τ - τ

study in Australia, 41-48, 476	Hospital
aims of, 44-45	Australian hospital system, 364-365
background, 42-43	duty of care, non-delegable, 364-374
conceptual framework, 47	circumstances where hospital owes, 368-372
consumer data collection, 45	obligation, what assumed, 368-369
current national inquiry, relationship with, 47	obligation, when not undertaken, 369-371
data analysis, integrated, 47	patient engages doctor directly, 371-372
data collection	status of hospital and patient, 372
consumer, 45	definition, 365-368
legal system, 46	delegation permissible, 365-366
third-party, 45-46	direct liability, 367
ethical clearance, 47	liability for delegates, 366-367
existing data and its limitations, 43-44	reasonable care by delegates, ensuring, 367
legal system data collection, 46	special relationship, existence of, 365
outcomes, anticipated, 48	strict liability, 368
overview of project, 44-48	employment, in course of, 372-374
research design, 44	
third-party data collection, 45-46	
	Indemnity insurance – see Medical indemnity
GeneTrustee, 506-513	insurance
see also Data registers	
accreditation and licensing of, 510	Infectious disease control – see Public health
alternative models, 511	
application of, 509-510	Information
criteria to be met, 510	see also Consent; Medical records; Privacy
development of, 509	provision of for patients, 178-186
diagram of, 512, 513	assessing patient's knowledge and
earlier GeneBroker model, 509	perceptions, 181-182
existing repositories, for, 510	style of communication, 178-180
expiry of custodianship, 510	timing of information, 181
implementation of model, 511	verbal communication, 180-181
limitations of model, 511	reinforced by written information, 182-183
parties involved in, 508, 512	video or computer, by, 184
role of, 508	written communication, 183-184
termination of custodianship, 510	learnability, 184
	legibility, 184
Guidelines	readability, 183-184
see also Clinical practice guidelines	reinforcing verbal communication, 182-
end-of-life, 397-398	183
	risks of treatment, about, 168-173
Guthrie cards, 507, 510	study of patients' wishes to know of, 168-173
	Insurance
Health care information – see Medical records;	see also Genetic discrimination; Medical
Privacy	indemnity insurance; Private health
· · · · · · · · ·	insurance
Health insurance – see Medicare; Private health	life
insurance	disability discrimination, 481, 483
	racial discrimination, 481-482
	,

International Criminal Court, 17-19

defence counsel, 18-19 evidence before, 19	Medical power of attorney, 260, 261
medical specialists, 17-18	Medical practitioners
practicalities of prosecutions, 17, 19	see also Complementary medicine
prosecutor, 18, 19	duty to potential abuse suspects, 25-26
investigative powers of, 19	rural services by, 385
types of cases before, 17	supervisory responsibility of specialists, 187-197
witnesses before, 19	Code of Health and Disability Services
Internet	Consumers' Rights, 189-193 clause 3 defence, 194-195
see also Pharmacy, online regulatory difficulties, 342-344	compliance with standards, 191-192
,	co-operation between providers, 193
anonymity, 343	informed, to be fully, 193
contractual issues, 344	reasonable care and skill, 190-191
flexibility of medium, 344	ethical tensions in setting standards, 193-195
jurisdiction, 342-343	keys to good supervision, 195-196
privacy issues, 344	supervision
	changes in nature and practice of, 188-189
	definition of, 187-188
Life support	keys to good, 195-196
withdrawal of, 26-27	
	Medical records
Limitations of actions	see also Data registers; Privacy; Research
medical practitioners, against, 388	autonomy of patient over, 460, 462
r r r	collection of information for, 412-413, 468
Living wills, 26	confidentiality, duty of
,	breach of confidence, 461, 464-467
Lung injury, transfusion-related, 266-267	disclose to other health professionals, 464-
= ing	467
	contract, in, 461
Medical indemnity insurance, 385-393	fiduciary relationship, 461
see also Damages; Negligence	tort, in, 461
"claims incurred" cover, 387-388	disclosure to other health professionals, 462-464
"claims made" cover, 387-388	best interests of patient, 462, 464, 465-466
	breach of confidence, extent to which, 464-
Commonwealth's rescue plan, 387-388	467
crisis in, 385-386	
limitation of actions, 388-389	basis and purpose of disclosure, 465
premiums, rise in, 385-386	confidential nature of information, 465
reasons for, 385-386	detriment to confidant, 465-466
tort law	public interest defence, 466-467
no-fault scheme, 392-393	consent
reform, 389-391	implied, 465, 469
Bolam principle, 389	validity of, 469
common practice in profession, 389	limitation on by privacy laws, 467-469
damages, 389-391	public interest, in, 466-467
good Samaritan law, 389	treating team, amongst, 462-464, 465, 466
New Zealand, in, 393	disclosure of, 468
United Kingdom, in, 393	meaning of, 464, 466
United States, in, 391, 392	discrimination using, 461

retention of system, 392-393 **Medical power of attorney**, 260, 261

doctors' proprietary rights over, 461	
electronic health records in Canada, 395-397	Necessity
information to be included, 396	see also Blood tests
use for secondary purposes, 397	defence, as criminal, 10-11
who is to have access to, 396-397	conjoined twins case, 12-13, 14, 15
protection of data, 462	current, 11-12
use and disclosure of information, 413, 468	elements of, 11
	Model Criminal Code Officers' Committee
Medical school	proposed model, 14
mini-medical school in Canada, 398	utilitarian doctrine, 13
,	doctrine of, 10-16
Medical treatment	medical treatment in "ordinary" situations, 14-16
see also Child; Complementary medicine;	
Consent; Drugs; Fetus	
artificial feeding and hydration as, 262-264	Negligence – see also Fetus; Psychiatric
best interests of patient, 26-27	injury; Tort law
refusal of, 26-27, 239-247	standards at time of incident, 409
capacity to decide, 240, 244-246	
criminal law, 242-244	Nervous shock – see Psychiatric injury
damages for unlawful trespass, 241	The four shoots see 1 by emilioned in July
fetus, effect on, 35-36	Norovirus, 267
guidance, 246-247	1101011143, 207
right to refuse life-sustaining treatment, 240-	Norwalk virus, 267
242	1101 Walk 111 us, 207
common law right, 242	Nurses
Convention rights, 242	administration of medication by enrolled, 158-
suicide, as, 242-243	162
standards at time of treatment, 409	accountability, 162
standards at time of treatment, 109	Australian Capital Territory, 161
Medicare	New South Wales, 160-161
Canada, in, 394-395	Northern Territory, 161-162
Canada, III, 65 1 556	Queensland, 159
Medications, opioid	South Australia, 160
legal liability for pain management involving,	Tasmania, 159-160
145-154	Victoria, 161
class actions by addicts, 153-154	Western Australia, 160
intentional wrongful conduct, 153	role of in patient care, 158-162
negligence and criminal law, in, 146-151	triage nurses, 401-405
breach of duty of care, 148-150	Australasian Triage Scale, 402
causation, 151	clinical responsibility of, 401-402
defences to negligence, 151-153	legal issues, potential, 404-405
assumption of risk, 151, 152	reality of triaging, 402-404, 405
contributory negligence, 152	reunty of triaging, 402 404, 403
duty, 147	
OxyContin, 149-150, 151, 153, 154	Online pharmacy – see Pharmacy, online
risks, advice about, 148-149	onine pharmacy – see I harmacy, unine
Tions, autice acout, 170 177	Opioid medications – see Medications, opioid
Medicine – see Complementary medicine;	Spiola medications see medications, opiola
Pharmacy, online	

Pain management

	50,
opioid medications for – see Medications,	reform suggestions, 359-362
opioid	Australian legislative reform, 359
	international co-operation, 360-361
Palliative care	Internet service providers, targeting, 361-
definition, 261	362
hastening death, 397-398	drug manufacturers and wholesalers,
right to refuse, 261	target,
,	361
Parens patriae power, 444-447 – see also Child	public awareness, 362
. ,	Therapeutic Goods Administration,
Patents	vigilance of, 362
stem cell research and – see Stem cell research	self-regulation, 357-358
	regulatory difficulties, 342-344
Pharmacy, online	anonymity, 343
advertising of medicines in Australia, online,	contractual issues, 344
351-354	flexibility of medium, 344
breach of regulations, 356	jurisdiction, 342-343
Australian online pharmacies, 344-349	privacy issues, 344
dispensing medicines from, 346-349	self-regulation, 357-358
guidelines for distance dispensing, 348-	webseals and trustmarks, 357-358
349	Therapeutic Goods Administration, 362
overseas consumers, to, 348	trustmarks, 357-358
pharmacy-only medicines, 346-347	webseals, 357-358
prescription-only medicines, 347-348	webseuis, 337 330
operation of, 346	Physiotherapy
regulations and administering bodies, 345	see also Cervical manipulation
	obligations of practitioner to advise on other
background information, 340-342	treatments, 303
benefits of, 341	treatments, 303
Internet service providers, targeting, 361	Daway of attorney modical 260 261
manufacturers and wholesalers, targeting, 361	Power of attorney, medical, 260, 261
overseas online pharmacies	Duran an an ann ann an afail ann Whan afail life alaims
importation of medicines, 351	Pregnancy, wrongful – see Wrongful life claims
need for regulation, 350	n '
regulation of generally, 349	Privacy
penalties and sanctions, effectiveness of, 354-	see also Data registers; Genetic
357	discrimination; Internet; Medical records;
advertising regulations, breach of, 356	Research
Pharmacy Board guidelines, breach of, 355-	areas of protection, 412-413
356	collection of information, 412-413, 468
statutory regulations for supply of drugs, breach of, 354-355	Commonwealth private sector scheme, 411, 418-419, 434, 467
United States, recent experience in, 356-357	collection of information, 419
regulation of, 339-363	health information, definition of, 418
Australian consumers and overseas online	National Privacy Principles, 72, 73-79, 411,
pharmacies, 349-351	418-420, 430, 468
Australian online pharmacies, 344-349	purposes of research, 419-420
online advertising of medicines in Australia,	sensitive information, 420
351-354	definition of, 418-419
JJ1-JJ 4	ucinition 01, 410-419
507	

penalties and sanctions, effectiveness of, 354-357

small business exception, 411, 467	Private Patient Charter, 336
type of information that can be used, 419	Canada, in, 394-395
Commonwealth public sector scheme, 411, 417-	community rating, 326, 327-328
418, 434, 467	competition between health funds, 333-335
Information Privacy Principles, 72, 411, 415,	loyalty bonuses, 334
416, 417	price discounting, 334-335
electronic health records, 395-397	selective contracting, 333-334
forensic medicine, issues for, 21	consumer access to, 326-330
health information, definition of, 418	community rating, 326, 327-328
importance of for health information, 461	control over benefits, 328-329
informing individual about use of information,	guaranteed access, 327
468	portability of coverage, 329-330
medical records, regarding, 460-469	financial solvency and industry viability, 330-
New South Wales, health records in, 468	333
outline of law, 411-413	prudential controls, 331
personal information, definition of, 411	health insurance business, definition of, 329
public interest, 429-431, 466-467	Medicare versus, 394-395
determinations, 429-431	pre-existing conditions, 331
research involving humans, effect on, 410-434	premiums, control over, 332-333
ethics requirement for compliance, 414-416	Private Health Insurance Ombudsman, 335-336
university research, 416-424	Private Patient Charter, 336
Victoria, schemes relevant in, 411	regulation of, 325-338
sensitive information, definition of, 418-419,	objectives, 326-337
468	accountability to consumers, promoting,
tort of, 467	335-337
use and disclosure of information, 413, 468	competition between health funds,
Victorian health privacy scheme, 19-24, 411,	promoting, 333-335
417, 423-424, 434	consumer access to, promoting, 326-330
Health Privacy Principles, 20, 23-24, 73, 411,	financial solvency and industry viability,
423-424, 425	promoting, 330-333
summary of, 23-24	reinsurance, 331-332
Health Records Act	report on, 326
exemptions, 21	waiting periods, 331
overview of, 20-21	Danahia tula indum
timeline for compliance, 20 Victorian public sector scheme, 411, 417, 421-	Psychiatric injury bearers of bad tidings, 140
423, 434	carelessness or breach of duty of care, 136-137
Information Privacy Act (Vic)	causation, 136
exemptions, 21	compensation for, 133-144
overview of, 20-21	death of baby, 406
Information Privacy Principles, 20, 22-23,	direct perception requirement, 134, 135, 139-140
411, 421-423, 425	litigation, 134-136
summary of, 22-23	nervous shock requirement, 138-139, 406-408
sensitive information, 422-423	normal fortitude requirement, 133, 135, 137-138
sonowie, i== i=s	psychiatric illness requirement, 136
Private health insurance	public policy considerations, 407-408
accountability to consumers, 335-337	reasonable foreseeability, 133, 134, 135, 137
consumer information, provision of, 336-337	recommendations of Ipp Inquiry, 141-142
Private Health Insurance Ombudsman, 335-	secondary victim, 406-407
336	sudden appreciation of events, 406-408

Public health, 435-441 AIDS, 436, 440

bioterrorism, 435, 440, 441	purposes of research, 419-420
drug laws, 437, 439	sensitive information, 420
gun control, 437	definition of, 418-419
infectious disease control, 435-436	type of information that can be used, 419
issues, 438-441	Commonwealth public sector scheme, 411,
agencies, links with other, 439	417-418
future, preparedness for the, 440-441	Information Privacy Principles, 72, 411,
reform and restructuring of, 436, 438-439	415, 416, 417
restating the case for, 439	legislation applicable, 424-425
risk management, 439	organisation from which information
scope of, 436-438	sought, 425
tobacco control, 437	researcher's organisation, 424-425
United States, in, 440	research exemptions in four schemes,
	comparison of, 434
	Victorian health privacy scheme, 411, 417,
Racial discrimination, 481-482	423-424
Tuesda discrimination, 101 102	Health Privacy Principles, 20, 23-24, 73,
Refusal of medical treatment – see Medical	411, 423-424, 425
treatment	summary of, 23-24
treatment	Victorian public sector scheme, 411, 417,
Registers, data – see Data registers	421-423
Registers, data see Data registers	Information Privacy Act (Vic)
Research	exemptions, 21
see also Privacy; Stem cell research	overview of, 20-21
agency's obligations to assist, 433	Information Privacy Principles, 20, 22-23,
consent by participants, 413-416	411, 421-423, 425
contacting individuals to obtain, 431-433	summary of, 22-23
exceptions to need for, 413, 414, 426	sensitive information, 422-423
necessity of, 425-426	social research, 428-431
requirements for, 414	federal privacy laws apply, where, 429
ethical regulation	public interest determinations, 429-431
consent requirements, 414	Victorian privacy laws, 431
	university research, 416-424
exceptions to, 413, 414 ethics committees	university research, 410-424
	Risks
application form identifying issues, 427	treatment, of – see Information
considering requests for access to	treatment, of – see information
information, 428	D
public interests, assessing competing, 428	Rural practitioners, 385
what required to do, 427	
which one to approve, 426	
National Statement, 47, 70, 73, 74, 76, 78, 79,	Sexual offences
80, 82, 413, 414, 415, 417, 426	see also Confidential communications
privacy law, compliance with, 414-416	legislation
privacy laws, effect of, 410-434	suspected abuse
Commonwealth private sector scheme, 411,	medical examination, 25-26
418-419	C'annua de la companya de la company
collection of information, 419	Siamese twins – see Conjoined twins

health information, definition of, 418 National Privacy Principles, 72, 73-79,

411, 418-420, 430

	proceedings against, 489, 501-502
Stem cell research , 488-505, 514-530	ethics, 492-493, 500-505
see also Cloning	Europe, in, 489, 492, 495, 500-504
Australia's international research status, 524,	European Biotechnology Directive, 500
525	European Group on Ethics in Science and
commercialisation of, 489	New Technologies, 502-504
community attitudes to, 493	inquiry into ethical aspects, 489, 502-504
consent of donors, 503	public order and morality, account of, 500
embryo	recommendation to prohibit patents, 492
arguments against use of, 519	Geron Corporation, 489, 491, 495-499
creation of for stem cells, 521, 524, 526, 528	Australia, patents in, 497
definition of, 522	challenges to patents, 497-498
destructive research	scope of patents of, 496-498
permitted, 523	importance of patent protection, 491-492
prohibited, 522, 524	bargaining power, 491, 495
development of, 515, 519-520, 523, 525	drug/therapeutic development, 491
donors of	licensing, 495
consent from, 528	industry perspectives, 491-492
financial inducements, 528	bargaining power, 491
ethical considerations for use of, 518-522	inquiry into, 494
United Kingdom, in, 519	IP Australia, policy of, 490-491
existing, use of, 521, 527-528	licensing provisions, 495, 504
human embryo, definition of, 525	parliamentary responses, 493-494
human embryo clone, definition of, 525-526	prohibition on patenting methods of human
hybrid embryo, definition of, 526	treatment, 489-490
legal status of, 518-519	Federal Court cases, erosion by, 490
moral status of, 518-522	research exemption, 499, 504
ethics in, 500-505	review of, need for, 491, 504-505
Europe, in, 489, 492, 495, 500-504	United States, in, 489, 495-499, 500
Edinburgh Patent, 489, 492, 500-502, 504	competition law, 499
European Group on Ethics in Science and	public order and morality, account of, 500
New Technologies, 502-504	research exemption, 499
Geron Corporation, 489, 491, 495-499	pharmaceutical industry stake in, 492
Australia, patents in, 497	regulation of, 522-528
challenges to patents, 497-498	alternative forms of, 493
scope of patents of, 496-498	destructive research prohibited, 522
stem cells as research tools, 498-499	emotional aspect of debate, 524
incompatibility of donors and recipients, 518	Ethical Guidelines, 522
National Centre for Excellence in Biotechnology	Gene Technology Act, 523
commercialisation of research, 489, 493	National Statement, 522
establishment of, 488	parliamentary committee recommendations,
National Stem Cell Bank, 492, 494	523-524
National Stem Cell Centre, 489, 494	Prohibition of Human Cloning Bill 2002, 525-
patent law and, 488-505	526
disadvantages of patent protection, 492, 495	Research Involving Embryos Bill 2002, 527-
profits driving research, 492	530
restrict research, 492, 494, 496, 498-499,	South Australia, in, 522
504	States working for consistency, 524
Edinburgh patent, 489, 492, 500-502, 504	United Kingdom, in, 528
disputed part of, 501	United States, in, 529

Victoria, in, 522	203, 204, 205
Western Australia, 522	agreements, 201
Research Involving Embryos Bill 2002, 527-530	Australian Capital Territory, 198, 200, 202-
developments leading up to, 522-525	203, 204, 205
embryos created before 5 April 2002, 527,	piecemeal approach, 198-199
528	commercial surrogacy, 203
licence requirements, 527, 528	common law jurisdictions, 200-201
licensing committee	future of, 213-219
establishment of, 527	accreditation model, 215-217
tasks of, 527, 529	judicial pre-authorisation model, 217
limitations of, 528-530	progressing the debate, 217-219
monitoring system, 528	legal impediments, 202-207
review of, 529, 530	medical practitioners, liability of, 202-203
stem cells	New South Wales, 198, 200-201, 206-207
adult, 515, 521, 529	Northern Territory, 198, 200-201
embryonic, 515 – see also embryo	parenthood, presumptions regarding, 204
benefits from use of, 517, 521	Queensland, 198-199, 200, 202, 203, 214
ethical considerations, 518-522	registration of commissioning parents as legal
trading in, 526, 528	parents, 204-205
multipotent, 515	residence disputes, resolution of, 202
pluripotent, 515	South Australia, 198, 200, 203
sources of, 517-518	statutory jurisdictions, 200
what are, 515	Tasmania, 198, 200, 202
technical and safety difficulties, 518	Victoria, 198, 200
therapeutic possibilities, 516	Western Australia, 198, 200-201
United States, in 489, 492, 495-497	definition, 198
competition law, 499	New Zealand, in, 208
limits on stem cell research, 495-497	United Kingdom, in, 207-208, 215
Wisconsin Alumni Research Foundation, 489, 495-498	United States, in, 208-209, 217
Succession law – see also Wills	Tort law
fetus, effect of on, 28-29, 38	see also Damages; Negligence
10tus, 01100t 01 011, 20 27, 30	no-fault scheme, 392-393
Suicide – see Euthanasia; Medical treatment	reform, 389-391
Sucree See Lucinanasia, Medicar treatment	Bolam principle, 389
Surrogacy, 198-220	common practice in profession, 389
arguments against, 209-213	damages, 389-391
detrimental to notions of family, 211	good Samaritan law, 389
devalues mothering role, 210-211	New Zealand, in, 393
exploitative of women, 209-210	United Kingdom, in, 393
not in child's best interests, 212	United States, in, 391, 392
residence disputes, difficulties from, 213	retention of system, 392-393
use of in "inappropriate" circumstances, 211-	•
212	Transfusion-related acute lung injury, 266-267
Australia, in, 198-207	9 9 9 1 2 1 2 2 2 3 3 3 3 3 3 3 3 3 3
adoption legislation	Triage – see Nurses
adequacy of, 205-207	
breach of, 207	Wills - see also Succession law
altruistic surrogacy, 198, 199, 200, 201, 202,	living, 26

Wrongful life claims, 163-167 breach of duty and causation, 165-166 damages, 166 duty of care, 165 public policy considerations, 166-167

Volume 10 581